Standard Biotools Inc (LAB) - Net Assets
Based on the latest financial reports, Standard Biotools Inc (LAB) has net assets worth $561.12 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($639.11 Million) and total liabilities ($77.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LAB tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $561.12 Million |
| % of Total Assets | 87.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | 348.53% |
| 10-Year Change | 697.05% |
| Growth Volatility | 81.88 |
Standard Biotools Inc - Net Assets Trend (2006–2025)
This chart illustrates how Standard Biotools Inc's net assets have evolved over time, based on quarterly financial data. See Standard Biotools Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Standard Biotools Inc (2006–2025)
The table below shows the annual net assets of Standard Biotools Inc from 2006 to 2025. For live valuation and market cap data, see LAB stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $424.29 Million | -10.05% |
| 2024-12-31 | $471.72 Million | +418.62% |
| 2023-12-31 | $-148.05 Million | -81.73% |
| 2022-12-31 | $-81.47 Million | -186.12% |
| 2021-12-31 | $94.60 Million | -31.97% |
| 2020-12-31 | $139.05 Million | -9.48% |
| 2019-12-31 | $153.61 Million | +113.01% |
| 2018-12-31 | $72.12 Million | +133.12% |
| 2017-12-31 | $30.93 Million | -41.89% |
| 2016-12-31 | $53.23 Million | -53.67% |
| 2015-12-31 | $114.90 Million | -23.61% |
| 2014-12-31 | $150.42 Million | +54.88% |
| 2013-12-31 | $97.12 Million | -3.52% |
| 2012-12-31 | $100.66 Million | +76.91% |
| 2011-12-31 | $56.90 Million | +130.08% |
| 2010-12-31 | $-189.17 Million | -8.96% |
| 2009-12-31 | $-173.62 Million | -9.65% |
| 2008-12-31 | $-158.34 Million | -21.49% |
| 2007-12-31 | $-130.33 Million | -22.75% |
| 2006-12-31 | $-106.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Standard Biotools Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 115227500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $404.00K | 0.10% |
| Other Comprehensive Income | $-1.49 Million | -0.35% |
| Other Components | $1.69 Billion | 397.35% |
| Total Equity | $424.29 Million | 100.00% |
Standard Biotools Inc Competitors by Market Cap
The table below lists competitors of Standard Biotools Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sword Group S.E
F:9RS
|
$316.28 Million |
|
Alucon Public Company Limited
BK:ALUCON
|
$316.43 Million |
|
Taiwan Optical Platform Co Ltd
TW:6464
|
$316.47 Million |
|
Regional Management Corp
NYSE:RM
|
$316.48 Million |
|
Perpetual Equity Investment Company Ltd
AU:PIC
|
$316.21 Million |
|
Keyfield International Berhad
KLSE:5321
|
$316.08 Million |
|
SUNDARAM CLAYTON LTD
NSE:SUNCLAY
|
$316.00 Million |
|
Kendrion NV
AS:KENDR
|
$315.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Standard Biotools Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 471,722,000 to 424,291,000, a change of -47,431,000 (-10.1%).
- Net loss of 74,896,000 reduced equity.
- Share repurchases of 1,054,000 reduced equity.
- Other comprehensive income decreased equity by 2,717,000.
- Other factors increased equity by 31,236,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.90 Million | -17.65% |
| Share Repurchases | $1.05 Million | -0.25% |
| Other Comprehensive Income | $-2.72 Million | -0.64% |
| Other Changes | $31.24 Million | +7.36% |
| Total Change | $- | -10.05% |
Book Value vs Market Value Analysis
This analysis compares Standard Biotools Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $-56.18 | $0.81 | x |
| 2007-12-31 | $-68.96 | $0.81 | x |
| 2008-12-31 | $-95.79 | $0.81 | x |
| 2009-12-31 | $-100.01 | $0.81 | x |
| 2010-12-31 | $-9.97 | $0.81 | x |
| 2011-12-31 | $3.19 | $0.81 | x |
| 2012-12-31 | $4.55 | $0.81 | x |
| 2013-12-31 | $3.81 | $0.81 | x |
| 2014-12-31 | $5.42 | $0.81 | x |
| 2015-12-31 | $4.00 | $0.81 | x |
| 2016-12-31 | $1.84 | $0.81 | x |
| 2017-12-31 | $0.94 | $0.81 | x |
| 2018-12-31 | $1.82 | $0.81 | x |
| 2019-12-31 | $2.30 | $0.81 | x |
| 2020-12-31 | $1.93 | $0.81 | x |
| 2021-12-31 | $1.25 | $0.81 | x |
| 2022-12-31 | $-1.04 | $0.81 | x |
| 2023-12-31 | $-1.87 | $0.81 | x |
| 2024-12-31 | $1.34 | $0.81 | x |
| 2025-12-31 | $1.11 | $0.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Standard Biotools Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -87.77%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.34x
- Recent ROE (-17.65%) is above the historical average (-38.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | -368.13% | 0.18x | 0.00x | $-12.94 Million |
| 2007 | 0.00% | -349.84% | 0.13x | 0.00x | $-12.42 Million |
| 2008 | 0.00% | -192.21% | 0.47x | 0.00x | $-13.67 Million |
| 2009 | 0.00% | -75.27% | 0.79x | 0.00x | $-1.77 Million |
| 2010 | 0.00% | -50.36% | 1.35x | 0.00x | $2.01 Million |
| 2011 | -39.49% | -52.42% | 0.54x | 1.39x | $-28.16 Million |
| 2012 | -18.90% | -36.35% | 0.46x | 1.13x | $-29.09 Million |
| 2013 | -16.29% | -22.23% | 0.61x | 1.20x | $-25.53 Million |
| 2014 | -35.12% | -45.36% | 0.29x | 2.71x | $-67.87 Million |
| 2015 | -46.40% | -46.48% | 0.31x | 3.23x | $-64.81 Million |
| 2016 | -142.74% | -72.75% | 0.34x | 5.76x | $-81.31 Million |
| 2017 | -195.68% | -59.38% | 0.35x | 9.29x | $-63.63 Million |
| 2018 | -81.83% | -52.24% | 0.37x | 4.21x | $-66.22 Million |
| 2019 | -42.18% | -55.26% | 0.44x | 1.72x | $-80.15 Million |
| 2020 | -38.13% | -38.38% | 0.43x | 2.34x | $-66.92 Million |
| 2021 | -62.62% | -45.36% | 0.47x | 2.91x | $-68.70 Million |
| 2022 | 0.00% | -194.08% | 0.25x | 0.00x | $-181.95 Million |
| 2023 | 0.00% | -70.21% | 0.33x | 0.00x | $-59.85 Million |
| 2024 | -29.44% | -79.62% | 0.28x | 1.30x | $-186.06 Million |
| 2025 | -17.65% | -87.77% | 0.15x | 1.34x | $-117.33 Million |
Industry Comparison
This section compares Standard Biotools Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,818,520,110
- Average return on equity (ROE) among peers: -48.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Standard Biotools Inc (LAB) | $561.12 Million | 0.00% | 0.14x | $316.24 Million |
| Abbott Laboratories (ABT) | $17.78 Billion | 20.28% | 1.23x | $153.89 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $15.55 Million |
| Aethlon Medical Inc (AEMD) | $-5.98 Million | 0.00% | 0.00x | $2.51 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.29 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $6.67 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $7.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.44 Million |
| Artivion Inc (AORT) | $17.90 Million | 7.26% | 0.20x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $176.29 Million |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more